Adenosine vs Diltiazem for Treatment of SVT in the ED

Last updated: May 26, 2026
Sponsor: Anne E. Zepeski
Overall Status: Active - Recruiting

Phase

4

Condition

Cardiac Disease

Heart Defect

Heart Disease

Treatment

diltiazem

adenosine

Clinical Study ID

NCT06993038
202412202
  • Ages 18-100
  • All Genders

Study Summary

This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Adult patients (18 years and older)

  2. Diagnosis of acute, stable SVT in the emergency department

Exclusion

Exclusion Criteria:

  1. Receipt of IV AV-nodal blocking agents prior to study enrollment (includesadenosine, non-dihydropyridine calcium channel blockers, beta-antagonists inpre-hospital and/or hospital setting).

  2. Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome

  3. History of heart failure with reduce ejection fraction (HFrEF) (LVEF</= 40%)

  4. Severe bronchoconstrictive lung disease

  5. Prior hypersensitivity to study medication

  6. Previously enrolled in pilot study

  7. Pregnant

  8. Incarcerated

Study Design

Total Participants: 20
Treatment Group(s): 2
Primary Treatment: diltiazem
Phase: 4
Study Start date:
August 01, 2025
Estimated Completion Date:
December 31, 2027

Connect with a study center

  • University of Iowa Health Care

    Iowa City, Iowa 52242
    United States

    Active - Recruiting

  • University of Iowa Health Care

    Iowa City 4862034, Iowa 4862182 52242
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.